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Abstract
Background: Co-infection with hepatitis B virus (HBV) and human immunodeficiency virus (HIV)
is not infrequent as both share same route of exposure. The risk of developing chronic hepatitis B
virus is 6%, in general population but can reach 10–20% in HBV/HIV co-infected patients. When
compared to general population, the response rate to HBV vaccine in HIV-infected patients is
diminished, so previous studies have tried to improve this response using variety of schedules,
doses and co-administration of immunomodulators. The purpose of this study was to evaluate two
doses of recombinant HBV vaccine (10 or 40 µg), IM at 0, 1 and 6 months. Vaccination response
was measured 30–50 days after last dose; titers of >9.9 IU/L were considered positive.
Results:  Seventy-nine patients were included, 48 patients (60.7%) serconverted. Thirty-nine
patients (49.3%) received 10 µg vaccine dose, 24 patients (61.5%) seroconverted. Forty patients
(50.7%) received 40 µg vaccine dose, 24 (60%) seroconverted. There were no differences between
two doses. A statistically significant higher seroconversion rate was found for patients with CD4
cell counts at vaccination ≥ 200 cel/mm3 (33 of 38 patients, 86.8%), compared with those with CD4
< 200 cel/mm3 (15 of 41, 36.6%), [OR 11.44, 95% IC 3.67–35.59, p = 0.003], there were no
differences between two vaccine doses. Using the logistic regression model, CD4 count <200 cel/
mm3 were significantly associated with non serologic response (p = 0.003). None other variables
such as gender, age, risk exposure for HIV, viral load, type or duration of HAART or AIDS-defining
illness, were asociated with seroconversion.
Conclusion: In this study, an increase dose of HBV vaccine did not show to increase the rate of
response in HIV infected subjects. The only significant findings associated to the response rate was
that a CD4 count ≥ 200 cel/mm3, we suggest this threshold at which HIV patients should be
vaccinated.
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Background
Hepatitis B virus (HBV) is one of the major causes of acute
and chronic hepatitis worldwide that can be prevented by
immunization [1,2].
Co-infection with HVB and human immunodeficiency
virus (HIV) is frequent as both share the same routes of
transmission [3]. In general population, risk of develop-
ing chronic hepatitis is 6%, but it can reach 10–20% in
HBV/HIV co-infected patients, besides this HBV/ HIV
patients present a higher level of HBV replication and
potential of transmission is increased [2,4-8]. HBV infec-
tion has been associated with more rapid progression to
AIDS, explained by an increased expression of HIV-
infected cells and faster decrease in CD4 lymphocytes [9-
12].
When compared to general population, the response rate
to HBV vaccine in HIV-infected patients, is diminished
(40–60% vs 60–80%) [10,13]. This lower response is
related with CD4 count less than 500 cel/mm3, and has
also been found with other antigens like influenza or
pneumococcal vaccines [14,15].
In previous studies including patients under hemodialy-
sis, the rate of response to HBV vaccine has been signifi-
cantly augmented by increasing dose, giving a fourth dose
of the vaccine or using immunomodulators agents such as
levamisole [2,16]. In HIV-patients the use of granulocyte-
macrophage colony-stimulating factor (GM-CSF) concur-
rent with HBV vaccine, has shown a significant increase in
seroconversion rate and in anti-HBs titers [17].
Currently, there are no data to determine the best HBV
vaccine schedule for HIV-infected patients. With the aim
to evaluate the rate of response to two different concentra-
tion of HBV vaccine in HIV-infected patients, we con-
ducted a controlled, randomized, clinical trial. We also
evaluated HIV viral load and CD4 counts at the time of
vaccination.
Methods
We conducted a double blind, randomized, controlled
trial using two different concentrations of HBV vaccine 10
or 40 µgs (Recombivax, HB, Merck, Sharp &Dohme, USA), in
two groups of HIV-infected patients stratified by CD4
count at time of vaccination (< 200 or ≥ 200 cel/mm3)
attending an HIV/AIDS Clinic at the Instituto Nacional de
Ciencias Médicas y de la Nutrición Salvador Zubirán and
at the Instituto Nacional de Cancerología in Mexico City.
The study was reviewed and approved by the Institutional
Committee of Human Biomedical Investigation (CIBH:
860 and CFEI: INF-0599900-1, approved on December
1999).
We included HIV-infected patients >16 years of age, nega-
tive for any HBV serological marker, not previously vacci-
nated, without active opportunistic infection at the time
of vaccination, who accepted to participate and signed
informed consent.
Patients were randomized to receive 10 or 40 µg of HBV
recombinant vaccine, 1 ml intramuscularly in the deltoid
region at 0, 1 and 6 months. We collected data on age,
gender, route to exposure for HIV infection, date for HIV
infection diagnosis, CD4 count and HIV viral load at the
first vaccine dose, type and time (in months) under
antiretroviral treatment and AIDS-defining event.
A technician who ignored vaccine dose, administered the
vaccine and collected a serum sample 40 ± 10 days after
third-dose application.
Quantitative anti-HBs test by IU/L (Microelisa system,
Hepanostika®  Anti-HBs New, Organon Tecknika, The
Netherlands) was performed. Negative samples for qual-
ity assurance were included. All sera were tested simulta-
neously. Response to vaccination was considered when
there was a rise in anti-HBs titers ≥ 10 IU/L. The absolute
count of CD4 lymphocytes was determined by a fuores-
cence-activate cell analyzer, using monoclonal antibodies.
The quantization of HIV-1 RNA was measured by AMPLI-
COR HIV-1 MONITOR® test was from 40 to 750,000 RNA
copies/mL.
Statistical analysis
We calculated an estimated 60% seroconversion rate for
the standard dose, an increase of 20% for the double dose
to be clinically significant. Eighty patients in each group
was required for a clinically difference.
We calculated seroconversion rate for each vaccine dose
by mean ± standard deviation for Student t test or Mann-
Whitney test for continuous variables were used as appro-
priate. For discrete variables, we used Chi-square or Fisher
exact test and reported odds ratios (ORs) with 95% confi-
dence interval (95% CI). P values ≤ 0.05 were considered
statistically significant.
Univariate analysis was used to test for associations
between independent (age, gender, vaccine dose, CD4
count and viral load at time of vaccination, time in
months from HIV diagnosis, treatment with HAART and
AIDS-defining event) and dependent variable (serocon-
version). A logistic regression model and a Cox model
were performed.
Results
Patients were recruited between April 1999 and May
2000. Eighty four patients were included. Five (6%) wereAIDS Research and Therapy 2006, 3:9 http://www.aidsrestherapy.com/content/3/1/9
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lost during follow-up [two (2.4%) in 10 µg dose and three
(3.6%) in 40 µg dose]. Characteristics of subjects who
completed the study and those who dropped out were
similar.
Non significant differences were found among demo-
graphic variables between the two groups. Age, gender,
CD4 count at vaccination, HIV viral load, history of an
AIDS defining event and antiretroviral therapy for each
group are depicted in Table 1.
The overall seroconversion rate after HBV vaccination was
60.7% (48 of 79 patients). For 10 µg vaccine dose, 24 of
39 patients (61.5%) seroconvert; and for 40 µg vaccine
dose, 24 of 40 patients (60%). Non significant difference
was found between two different vaccine concentrations
[relative risk (RR) = 1.1; 95% confidence interval (CI) =
0.61–1.98, p = 0.889].
Stratified by CD4 count, 33 of 38 patients (86.8%) with
CD4 ≥ 200 cel/mm3 seroconverted, compared with 15 of
41 patients with < 200 cel/mm3 (36.5%), (OR = 11.4,
95% CI = 3.6–35.6, p = 0.003). Stratified by viral load, 12
of 15 patients with < 400 copies/mL seroconverted (80%),
and 30 of 51 patients with ≥ 400 copies/mL (58.8%), (OR
0.45, 95% CI= 0.22–0.92, p = 0.29).
Patients with CD4 < 200 cel/mm3 and viral load < 400
copies/mL, showed higher seroconversion rates, but only
CD4 count was statistically significant. No diference was
observed with two different vaccine doses.
Variables included in the logistic regression model were
vaccine dose, CD4 count, viral load, HAART treatment,
AIDS-defining illness, gender and risk factor for HIV infec-
tion. Only CD4 count <200 cel/mm3 was associated with
non seroconversion.
Table 1: Characteristics of HIV-infected patients. Baseline clinical and demographic characteristics of HIV-infected patients, who 
completed the study (n = 79)
Variables Vaccine 10 µg Vaccine 40 µgp
No. patients (%) 39 (49.3) 40 (50.7) -
Gender male – No. (%) 27 (69.2) 29 (72.5) 0.749
Mean age (years ± s.d.) 35.6 ± 8.12 34.1 ± 7.6 0.378
HIV exposure – No. (%)
Heterosexual 18 (45%) 16 (41%) 0.721
Homo or bisexual 22 (55%) 23 (59%)
Diagnosis of HIV (months ± s.d.) 40.6 ± 35.4 40.2 ± 32.65 0.960
Mean CD4 count (cel/mm3 ± s.d.) 245 ± 217.9 225.45 ± 189.7 0.671
CD4 cel/mm3 / No. (%)
< 200 20 (51.3%) 21 (52.5%) 0.914
≥ 200 19 (48.8%) 19 (47.5%)
Viral load (copies/mL) 75,187 ± 153,305 67,335 ± 112,742 0.811
Viral load (copies/mL) – No. (%)
≤ 400 6 (20%) 9 (25%) 0.860
400 – ≤ 20,000 11 (36.6%) 11 (30.6%)
≥ 20,000 13 (43.3%) 16 (44.4%)
AIDS-defining illness – No. (%) 17 (43.6) 10 (25) 0.082
Treatment with HAART* – No. 
(%)
22 (56.4) 29 (72.5) 0.135
PI 20 (51.2) 23 (57.5)
NNRTI 1 (2.6) 4 (10)
PI + NNRTI or 3 NRTI 1 (2.6) 2 (5)
PI: Protease inhibitor; NNRTI: non-nucleoside reverse transcriptase inhibitor; NRTI: Nucleoside reverse transcriptase inhibitor.AIDS Research and Therapy 2006, 3:9 http://www.aidsrestherapy.com/content/3/1/9
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Mean anti-HBs titers were 137.3 ± 56.7IU/L for the 10 µg
vaccine dose and 144.1 IU/L ± 56.7 for the 40 µg vaccine
dose (p=ns). Titers post-vaccination are shown in Figure
1. Titers were significantly higher in patients with CD4 ≥
200 cel/mm3 compared with those with CD4 < 200 cel/
mm3 (107.2 ± 56.7 IU/L vs 39.7 ± 35.4 IU/L, p < 0.005).
HBV vaccine was well tolerated by all patients; two
patients reported pain at the injection site, one with ery-
thema. No serious adverse events were registered.
Discussion
Approximately 90–97% of healthy adults will show pro-
tective anti-HBs titers after vaccination with recombinant
HBV vaccine [18,19]. As previously reported [7,20,21], we
found a lower rate of response in this cohort of HIV-
infected patients vaccinated with HBV recombinant vac-
cine (60.7%) of the population fully immunized, increas-
ing vaccine did not have a beneficial effect.
Risk factors significantly associated to failure of vaccina-
tion in previously reports, were the degree of immunosup-
pression and clinical markers of advanced HIV disease like
CD4 count at vaccination and history of an AIDS-defining
event. We found that the factor most strongly associated
with non seroconversion and lower anti-HBs titers was
CD4 count <200 cel/mm3. Previous studies with other
antigens (like influenza or 23-valent pneumococcal vac-
cines) have shown lesser response asocciated with lower
CD4 counts [14,15].
There are numerous reports describing a variety of dose
schedules, limited success and markers associated with
impaired response to HBV vaccine in these individuals.
Most studies have been small in size sample making it dif-
ficult to draw conclusions within and between studies.
Recently Fonseca et al, found higher serconversion with
double vaccine dose in those patients with CD4 count ≥
350 cel/mm3 and low HIV viremia, with no differences
between two different vaccine doses in patients with CD4
< 350 cel/mm3 [22].
This study was performed with a smaller sample that ini-
tially calculated as we found trouble in getting non vacci-
nated or non infected HBV patients. Because of the small
size, the power to determine differences between the two
dosages of vaccine is low resulting in the possibility of a
type II error. We found that the CD4 nadir (<200 cel/
mm3) of patients whose CD4 increase with HAART over ≥
200 had a similar rate of response when compared to
patients with persistent CD4≥ 200 cel/mm3(data not pre-
sented); this finding should be interpreted with caution, it
could be related to the small sample size. One interesting
point is to investigate in the future the duration of this
increase to achieve best rate of response in HIV-infected
patients receiving HAART.
No seroconversion differences were found between this
risk groups among homosexual, bisexual or heterosexual
patients as has previously reported in other studies
[1,2,18,20]. In this sample no patients had a history of
drug abuse probably to the low number of HIV infected
patients associated to this risk factor in Mexico less than
Table 2: Logistic regression model. Independent variables associated with non-seroconversion
OR* OR adjusted [CI 95%] p
Vaccine dose 10 µg - 0.937 ± 0.432 [0.27–2,31] 0.889
CD4 < 200 cel/mm3 1.21 [0.3–4.9] 11.44 ± 6.62 [3.67–35.59] 0.003
Viral load ≥ 40 copies/mL 0.82 [0.17–3.82] 0.451 ± 0.164 [0.22–0.92] 0.029
Non HAART treatment 0.58 [0.15–2.23] 0.649 ± 0.201 [0.35–1.19] 0.164
AIDS-defining illness 2.5 [0.54–12.29] 0.972 ± 0.333 [0.49–1.9] 0.934
Gender male 0.75 [0.13–4.27] 0.806 ± 0.266 [0.42–1.54] 0.517
Homosexual or bisexual 0.6 [0.16–2.2] 0.844 ± 0.251 [0.47–1.51] 0.569
* OR=odds ratio
Titers post-vaccination Figure 1
Titers post-vaccination. Titers post-vaccination catego-
rized in four groups, with two different vaccine concentra-
tions (UI/mL).
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1%. None other risk factors as age, gender, type or dura-
tion of HAART or history of AIDS-defining event were
related with serconversion.
We did not find any serious adverse event related with
HBV vaccination in this group of patients as HIV and HBV
share the same routes of exposure, we recommend vacci-
nating HIV patients against HBV.
Conclusion
Although the sample study is small to give a definite con-
clusion, increasing the does not appears to contribute to
HVB vaccine seroconversion. This study confirms previ-
ous reports that HIV-infected patients have a poor immu-
nologic response to HBV vaccine, but a CD4 count
threshold is ≥ 200 cell/mm3 appears to increase vaccina-
tion response independently to vaccine dosing, as has
been show by other studies.
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